4115 OLE-OPTH-OA-2008-2(4)-Anglade.pdfUveitis is an inflammatory autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Currently available therapies are burdened with toxicities and/or lack definitive evidence of efficacy. Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile and a wide therapeutic window. If successful, voclosporin will become the first Food and Drug Administration-approved corticosteroid-sparing agent for this condition.
No comments:
Post a Comment
Leave a Comment or Question: